Physician profile
Troy D Bell
NPI 1174537690
$4,886.46
in general payments reported to CMS, 2019-2025
14 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $121 · 2021: $485 · 2022: $687 · 2023: $590 · 2024: $777 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,313.41 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Johnson & Johnson Vision Care, INC. | $768.54 | 2021-2025 | Acuvue |
| Coopervision INC. | $418.51 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $396.86 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $366.71 | 2024-2025 | Infuse |
| Glaukos Corporation | $297.10 | 2020-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Abbvie INC. | $162.56 | 2022-2025 | |
| Dompe US, INC. | $50.06 | 2024 | Oxervate |
| Allergan, INC. | $25.63 | 2021 | |
| Sight Sciences, INC. | $24.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.88 | 2020 | |
| Lombart Brothers, INC. | $16.23 | 2021 | |
| Amgen INC. | $14.12 | 2025 | Tepezza |
| Lkc Technologies, INC. | $9.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.